Study S000264

Effects of the Glucagon Like-peptide 1 (GLP-1) Receptor Agonist Liraglutide on Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: a Randomized Controlled Trial

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT04881110
Acronym: STARDUST
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: COMPLETED
Enrollment: 60
Start: 2021-02-01
Primary completion: 2022-12-31
Lead sponsor: University of Campania Luigi Vanvitelli
Conditions: Type 2 Diabetes; Peripheral Arterial Disease
Interventions: DRUG:Liraglutide; OTHER:Control
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Peripheral Transcutaneous Oxygen Pressure [6 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008968	Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial. Caruso P, JAMA network open	2024	Randomized trial	PMID 38470420 DOI	cites ClinicalTrials.gov:NCT04881110; registry reference DERIVED:38470420
R0016220	Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope? Caruso P, Diabetes/metabolism research and reviews	2023	Randomized trial	PMID 36812501 DOI	cites ClinicalTrials.gov:NCT04881110; registry reference RESULT:36812501